CTX120 (NCT04244656) is an allogeneic CAR T therapy developed by CRISPR Therapeutics, Inc. that targets and edits the B cell maturation antigen (BCMA) of a healthy donor via CRISPR–Cas9, CTX120 has been used in clinical trials to evaluate its efficacy and safety in the treatment of MM.394. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.